FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087694430> ?p ?o ?g. }

• W2087694430 endingPage "2111" @default.
• W2087694430 startingPage "2099" @default.
• W2087694430 abstract "The mitogen-activated protein kinases (MAPK) have been shown to participate in iNOS induction following lipopolysaccharide (LPS) stimulation, while the role of MAPKs in the regulation of arginase remains unclear. We hypothesized that different MAPK family members are involved in iNOS and arginase expression following LPS stimulation. LPS-stimulated RAW 264.7 cells exhibited increased protein and mRNA levels for iNOS, arginase I, and arginase II; although the induction of arginase II was more robust than that for arginase I. A p38 inhibitor completely prevented iNOS expression while it only attenuated arginase II induction. In contrast, a MEK1/2 inhibitor (ERK pathway) completely abolished arginase II expression while actually enhancing iNOS induction in LPS-stimulated cells. Arginase II promoter activity was increased by ∼4-fold following LPS-stimulation, which was prevented by the ERK pathway inhibitor. Arginase II promoter activity was unaffected by a p38 inhibitor or JNK pathway interference. Transfection with a construct expressing a constitutively active RAS mutant increased LPS-induced arginase II promoter activity, while transfection with a vector expressing a dominant negative ERK2 mutant or a vector expressing MKP-3 inhibited the arginase II promoter activity. LPS-stimulated nitric oxide (NO) production was increased following siRNA-mediated knockdown of arginase II and decreased when arginase II was overexpressed. Our results demonstrate that while both the ERK and p38 pathways regulate arginase II induction in LPS-stimulated macrophages, iNOS induction by LPS is dependent on p38 activation. These results suggest that differential inhibition of the MAPK pathway may be a potential therapeutic strategy to regulate macrophage phenotype.Arginase and iNOS induction are key to macrophage polarization and function.ResultsERK activation is needed for arginase induction in activated macrophages and the M2 phenotype.ConclusionMAP kinase family members have distinct and opposing roles in activating iNOS and arginase.SignificanceERK and p38 may represent novel therapeutic targets for regulating macrophage phenotype in inflammatory diseases. The mitogen-activated protein kinases (MAPK) have been shown to participate in iNOS induction following lipopolysaccharide (LPS) stimulation, while the role of MAPKs in the regulation of arginase remains unclear. We hypothesized that different MAPK family members are involved in iNOS and arginase expression following LPS stimulation. LPS-stimulated RAW 264.7 cells exhibited increased protein and mRNA levels for iNOS, arginase I, and arginase II; although the induction of arginase II was more robust than that for arginase I. A p38 inhibitor completely prevented iNOS expression while it only attenuated arginase II induction. In contrast, a MEK1/2 inhibitor (ERK pathway) completely abolished arginase II expression while actually enhancing iNOS induction in LPS-stimulated cells. Arginase II promoter activity was increased by ∼4-fold following LPS-stimulation, which was prevented by the ERK pathway inhibitor. Arginase II promoter activity was unaffected by a p38 inhibitor or JNK pathway interference. Transfection with a construct expressing a constitutively active RAS mutant increased LPS-induced arginase II promoter activity, while transfection with a vector expressing a dominant negative ERK2 mutant or a vector expressing MKP-3 inhibited the arginase II promoter activity. LPS-stimulated nitric oxide (NO) production was increased following siRNA-mediated knockdown of arginase II and decreased when arginase II was overexpressed. Our results demonstrate that while both the ERK and p38 pathways regulate arginase II induction in LPS-stimulated macrophages, iNOS induction by LPS is dependent on p38 activation. These results suggest that differential inhibition of the MAPK pathway may be a potential therapeutic strategy to regulate macrophage phenotype.Arginase and iNOS induction are key to macrophage polarization and function. ERK activation is needed for arginase induction in activated macrophages and the M2 phenotype. MAP kinase family members have distinct and opposing roles in activating iNOS and arginase." @default.
• W2087694430 created "2016-06-24" @default.
• W2087694430 creator A5010579783 @default.
• W2087694430 creator A5076167118 @default.
• W2087694430 creator A5076748283 @default.
• W2087694430 date "2015-01-01" @default.
• W2087694430 modified "2023-10-14" @default.
• W2087694430 title "Extracellular Signal-regulated Kinase Mediates Expression of Arginase II but Not Inducible Nitric-oxide Synthase in Lipopolysaccharide-stimulated Macrophages" @default.
• W2087694430 cites W1580087656 @default.
• W2087694430 cites W1968590447 @default.
• W2087694430 cites W1969543607 @default.
• W2087694430 cites W1979113069 @default.
• W2087694430 cites W1984903682 @default.
• W2087694430 cites W1991992481 @default.
• W2087694430 cites W1994044284 @default.
• W2087694430 cites W1995014753 @default.
• W2087694430 cites W2001927863 @default.
• W2087694430 cites W2007497409 @default.
• W2087694430 cites W2010453472 @default.
• W2087694430 cites W2013471060 @default.
• W2087694430 cites W2015583679 @default.
• W2087694430 cites W2019209562 @default.
• W2087694430 cites W2031380876 @default.
• W2087694430 cites W2038461328 @default.
• W2087694430 cites W2038689279 @default.
• W2087694430 cites W2041873965 @default.
• W2087694430 cites W2042786467 @default.
• W2087694430 cites W2042832398 @default.
• W2087694430 cites W2046867705 @default.
• W2087694430 cites W2054791134 @default.
• W2087694430 cites W2068842251 @default.
• W2087694430 cites W2078265535 @default.
• W2087694430 cites W2093788957 @default.
• W2087694430 cites W2093965961 @default.
• W2087694430 cites W2095400574 @default.
• W2087694430 cites W2107790283 @default.
• W2087694430 cites W2119670701 @default.
• W2087694430 cites W2120562230 @default.
• W2087694430 cites W2159827287 @default.
• W2087694430 cites W2164087707 @default.
• W2087694430 cites W2164876856 @default.
• W2087694430 cites W2314205299 @default.
• W2087694430 doi "https://doi.org/10.1074/jbc.m114.599985" @default.
• W2087694430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4303663" @default.
• W2087694430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25451938" @default.
• W2087694430 hasPublicationYear "2015" @default.
• W2087694430 type Work @default.
• W2087694430 sameAs 2087694430 @default.
• W2087694430 citedByCount "30" @default.
• W2087694430 countsByYear W20876944302015 @default.
• W2087694430 countsByYear W20876944302016 @default.
• W2087694430 countsByYear W20876944302017 @default.
• W2087694430 countsByYear W20876944302018 @default.
• W2087694430 countsByYear W20876944302019 @default.
• W2087694430 countsByYear W20876944302020 @default.
• W2087694430 countsByYear W20876944302021 @default.
• W2087694430 countsByYear W20876944302022 @default.
• W2087694430 countsByYear W20876944302023 @default.
• W2087694430 crossrefType "journal-article" @default.
• W2087694430 hasAuthorship W2087694430A5010579783 @default.
• W2087694430 hasAuthorship W2087694430A5076167118 @default.
• W2087694430 hasAuthorship W2087694430A5076748283 @default.
• W2087694430 hasBestOaLocation W20876944301 @default.
• W2087694430 hasConcept C104317684 @default.
• W2087694430 hasConcept C134018914 @default.
• W2087694430 hasConcept C153911025 @default.
• W2087694430 hasConcept C164007495 @default.
• W2087694430 hasConcept C184235292 @default.
• W2087694430 hasConcept C185592680 @default.
• W2087694430 hasConcept C2777468819 @default.
• W2087694430 hasConcept C2777622882 @default.
• W2087694430 hasConcept C2778754761 @default.
• W2087694430 hasConcept C515207424 @default.
• W2087694430 hasConcept C51551487 @default.
• W2087694430 hasConcept C519581460 @default.
• W2087694430 hasConcept C54009773 @default.
• W2087694430 hasConcept C55493867 @default.
• W2087694430 hasConcept C57074206 @default.
• W2087694430 hasConcept C62478195 @default.
• W2087694430 hasConcept C86803240 @default.
• W2087694430 hasConcept C95444343 @default.
• W2087694430 hasConceptScore W2087694430C104317684 @default.
• W2087694430 hasConceptScore W2087694430C134018914 @default.
• W2087694430 hasConceptScore W2087694430C153911025 @default.
• W2087694430 hasConceptScore W2087694430C164007495 @default.
• W2087694430 hasConceptScore W2087694430C184235292 @default.
• W2087694430 hasConceptScore W2087694430C185592680 @default.
• W2087694430 hasConceptScore W2087694430C2777468819 @default.
• W2087694430 hasConceptScore W2087694430C2777622882 @default.
• W2087694430 hasConceptScore W2087694430C2778754761 @default.
• W2087694430 hasConceptScore W2087694430C515207424 @default.
• W2087694430 hasConceptScore W2087694430C51551487 @default.
• W2087694430 hasConceptScore W2087694430C519581460 @default.
• W2087694430 hasConceptScore W2087694430C54009773 @default.
• W2087694430 hasConceptScore W2087694430C55493867 @default.
• W2087694430 hasConceptScore W2087694430C57074206 @default.
• W2087694430 hasConceptScore W2087694430C62478195 @default.
• W2087694430 hasConceptScore W2087694430C86803240 @default.

• next